Showing results (1-10 of 21) with videos related to
Sort By:
Pageof 3
Molecular Cancer Research : MCR|February 14, 2018
BET Proteins Exhibit Transcriptional and Functional Opposition in the Epithelial-to-Mesenchymal TransitionGuillaume P Andrieu, Gerald V DenisMolecular Cancer Research : MCR|May 22, 2019
BRD4 Regulates Metastatic Potential of Castration-Resistant Prostate Cancer through AHNAKJordan S Shafran, Guillaume P Andrieu, Balázs Györffy, et al.Journal of Leukocyte Biology|March 2, 2018
BET proteins in abnormal metabolism, inflammation, and the breast cancer microenvironmentGuillaume P Andrieu, Jordan S Shafran, Jude T Deeney, et al.Cancer Letters|September 2, 2019
BET protein targeting suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer and elicits anti-tumor immune responseGuillaume P Andrieu, Jordan S Shafran, Charlotte L Smith, et al.Blood Advances|February 9, 2021
Adenylate kinase 2 expression and addiction in T-ALLNabih Maslah, Mehdi Latiri, Vahid Asnafi, et al.Blood Advances|November 15, 2024
ATP citrate lyase is an essential player in the metabolic rewiring induced by PTEN loss during T-ALL developmentGuillaume P Andrieu, Guillaume Hypolite, Mehdi Latiri, et al.Blood|June 14, 2021
PRC2 loss of function confers a targetable vulnerability to BET proteins in T-ALLGuillaume P Andrieu, Milena Kohn, Mathieu Simonin, et al.Nature Communications|March 4, 2025
A metabolic synthetic lethality of phosphoinositide 3-kinase-driven cancerGuillaume P Andrieu, Mathieu Simonin, Aurélie Cabannes-Hamy, et al.Blood|August 26, 2025
LEF1 Intragenic Deletion Induces a Dominant-Negative isoform and unveils a Wnt/β3-Catenin Vulnerability in T-ALLManon Delafoy, Mickaël Frédéric Bonnet, Etienne Lengliné, et al.Science Translational Medicine|May 27, 2021
Epigenetic analysis of patients with T-ALL identifies poor outcomes and a hypomethylating agent-responsive subgroupAurore Touzart, Anand Mayakonda, Charlotte Smith, et al.Pageof 3